Novel LABA / LAMA formulation & novel COPD therapy formulation

As part of Circassia’s strategy to broaden its portfolio we are using our respiratory expertise to deliver additional in-house development programs.  We are currently undertaking development work on two novel formulations of currently approved drugs for an underserved segment of the specialist moderate-to-severe COPD field.

Product overviews

Circassia’s first formulation contains a LABA / LAMA fixed dose combination, which third-party research estimates is targeting a patient population of up to 350,000 in the US and EU5. The product incorporates novel next generation nebulization technology that we recently in-licensed from leading medical innovation company Philips Respiratory Drug Delivery. The easy-to-use nebulizer is hand-held and web enabled, allowing efficient data collection.

The second formulation is targeting reductions in COPD exacerbations and the US / EU5 target patient population totals up to 200,000.

Formulation development work is progressing well, and the most advanced of the two products, the fixed dose LABA/ LAMA, is on track to begin an initial clinical study in 2018.

 

Pipeline status: Novel LABA / LAMA formulation

ResearchPre-clinicalPhase IPhase IIPhase III /
Substitute
Approved

Pipeline status: Novel COPD therapy formulation

ResearchPre-clinicalPhase IPhase IIPhase III /
Substitute
Approved

View Circassia's full pipeline chart